(Q34469806)

2 August 2017

1 reference

title

Host-Salmonella interaction: human trials (English)

1 reference

2 August 2017

M M Levine

1

1 reference

PubMed ID

11755415

2 August 2017

C O Tacket

series ordinal

2

1 reference

PubMed ID

11755415

2 August 2017

M B Sztein

series ordinal

3

1 reference

2 August 2017

1 November 2001

1 reference

2 August 2017

Microbes and Infection

1 reference

2 August 2017

3

1 reference

2 August 2017

1271-1279

1 reference

2 August 2017

14-15

1 reference

Typhoid fever: pathogenesis and immunologic control

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Immunity of cholera in man: Relative role of antibacterial versus antitoxic immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Immunity to Enterotoxigenic Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Attenuated, Streptomycin-Dependent Salmonella typhi Oral Vaccine: Potential Deleterious Effects of Lyophilization

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Protective activity of Vi capsular polysaccharide vaccine against typhoid fever

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Isolation and Characterization of Gal E Mutant Ty 21a of Salmonella typhi: A Candidate Strain for a Live, Oral Typhoid Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Construction of genetically defined double aro mutants of Salmonella typhi

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Evaluation of Salmonella typhimurium strains harbouring defined mutations in htrA and aroA in the murine salmonellosis model

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Characterization of defensin resistance phenotypes associated with mutations in the phoP virulence regulon of Salmonella typhimurium

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

A two-component regulatory system (phoP phoQ) controls Salmonella typhimurium virulence.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Progress in vaccines against typhoid fever

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Vi serology in detection of chronic Salmonella typhi carriers in an endemic area

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Characterization of defined ompR mutants of Salmonella typhi: ompR is involved in the regulation of Vi polysaccharide expression

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

The RcsB-RcsC regulatory system of Salmonella typhi differentially modulates the expression of invasion proteins, flagellin and Vi antigen in response to osmolarity.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Identification of an intestinal immune response using peripheral blood lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Specific immune response in humans following rectal delivery of live typhoid vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2801%2901487-3

7 January 2021

10.1016/S1286-4579(01)01487-3

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11755415